JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Hologic Inc

Închisă

SectorSănătate

74.02 0.16

Rezumat

Modificarea prețului

24h

Curent

Minim

73.84

Maxim

74.1

Indicatori cheie

By Trading Economics

Venit

212M

195M

Vânzări

19M

1B

P/E

Medie Sector

28.98

37.461

EPS

1.08

Marjă de profit

19.037

Angajați

7,063

EBITDA

341M

334M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+5.42% upside

Dividende

By Dow Jones

Următoarele câștiguri

3 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.3B

16B

Deschiderea anterioară

73.86

Închiderea anterioară

74.02

Sentimentul știrilor

By Acuity

25%

75%

51 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Hologic Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 oct. 2025, 13:20 UTC

Achiziții, Fuziuni, Preluări

Blackstone, TPG to Buy Hologic for Up to $18.3 Billion

27 mai 2025, 18:46 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Hologic Shares Up Following Report of Buyout Offer From TPG, Blackstone

21 oct. 2025, 16:36 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Hologic Seen as Prime Take-Private Candidate -- Market Talk

21 oct. 2025, 13:05 UTC

Achiziții, Fuziuni, Preluări

Blackstone, TPG to Buy Hologic for Up to $18.3B

21 oct. 2025, 12:50 UTC

Achiziții, Fuziuni, Preluări

Hologic Plans to File Form 10-K for Fiscal 2025 With the SEC in Late Nov >HOLX

21 oct. 2025, 12:49 UTC

Achiziții, Fuziuni, Preluări

Hologic Does Not Intend to Provide Fincl Guidance for FY26 in Upcoming 4Q Results Release

21 oct. 2025, 12:48 UTC

Achiziții, Fuziuni, Preluări

Hologic Merger Agreement Includes a 45-Day 'Go-Shop' Period >HOLX

21 oct. 2025, 12:48 UTC

Achiziții, Fuziuni, Preluări

Hologic Will Continue to Operate Under the Hologic Name and Brand >HOLX

21 oct. 2025, 12:48 UTC

Achiziții, Fuziuni, Preluări

Hologic Will Maintain Its Headquarters in Marlborough, Massachusetts >HOLX

21 oct. 2025, 12:47 UTC

Achiziții, Fuziuni, Preluări

Blackstone's Private Equity Strategy for Individual Investors Is Also Expected to Invest as Part of Transaction

21 oct. 2025, 12:46 UTC

Achiziții, Fuziuni, Preluări

Blackstone and TPG Secured Committed Financing From Citi, Bank of Amer, Barclays, Royal Bank of Canada and SMBC

21 oct. 2025, 12:46 UTC

Achiziții, Fuziuni, Preluări

Blackstone and TPG Have Secured Committed Financing for the Transaction >HOLX

21 oct. 2025, 12:45 UTC

Achiziții, Fuziuni, Preluări

Hologic: Transaction Includes Significant Minority Investments From Subsidiary of Abu Dhabi Investment Authority and an Affil of GIC >HOLX

21 oct. 2025, 12:45 UTC

Achiziții, Fuziuni, Preluări

Hologic: Purchase Price Represents Premium of About 46% to Closing Price on May 23 >HOLX

21 oct. 2025, 12:45 UTC

Achiziții, Fuziuni, Preluări

Hologic: Non-tradable CVR Would Be Issued to Holders at Closing and Paid Following Achievement of Certain Global Rev Goals for Breast Health Business in FY26, FY27

21 oct. 2025, 12:44 UTC

Achiziții, Fuziuni, Preluări

Blackstone and TPG Will Acquire Hologic Shrs for $76/Shr in Cash Plus Non-Tradable CVR to Get Up to $3/Shr for Total of Up to $79/Shr in Cash >HOLX

21 oct. 2025, 12:42 UTC

Achiziții, Fuziuni, Preluări

Hologic: Transaction Will Help Strengthen Leadership in Women's Health and Accelerate Growth >HOLX

21 oct. 2025, 12:42 UTC

Achiziții, Fuziuni, Preluări

Hologic to Be Acquired by Funds Managed by Blackstone Deal and TPG in Deal With Enterprise Value of Up to $18.3 B >BX HOLX

27 mai 2025, 20:07 UTC

Achiziții, Fuziuni, Preluări

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27 mai 2025, 19:06 UTC

Achiziții, Fuziuni, Preluări

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27 mai 2025, 18:26 UTC

Achiziții, Fuziuni, Preluări

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 19%. -- Barrons.com

Comparație

Modificare preț

Hologic Inc Așteptări

Obiectiv de preț

By TipRanks

5.42% sus

Prognoză pe 12 luni

Medie 78 USD  5.42%

Maxim 94 USD

Minim 69 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHologic Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

13 ratings

3

Cumpărare

10

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

52.69 / 58.605Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

51 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Hologic Inc

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat